Business
CSL profits boom 45pc as flu business soars – The Australian Financial Review
The blood products giant notched up its fastest profit and revenue growth in recent years despite a uniquely challenging first half.
Sales of CSLs Hizentra product grew strongly, up 19 per cent, reflecting the benefits of home administration and the continued strong uptake for the treatment of the debilitating neurological disorder CIDP (chronic inflammatory demyelinating polyneuropathy).
The company declared a dividend of $US1.04 per share, up 9 per cent.
Guidance maintained
Despite the strong growth in the first half, the company maintained its full-year guidance of net profit of $US2.17 billion to $US2.265 billion at constant…
-
Business20 hours agoMacquarie tips 14% upside for this ASX tech stock
-
Noosa News16 hours agoWilliam Robinson dies aged 89
-
Business18 hours agoTop brokers name 3 ASX shares to buy today 27 August 2025
-
Business20 hours agoThis ASX 200 media stock is storming 7% higher to 52-week highs. Here’s why.